Amarin (Nasdaq: $AMRN) Stock Hub 2026: $314.6 Million Of Cash And No Debt Against A $297.2 Million Market Value, After The Supreme Court Ruling And The Recordati Model

01 What Amarin Is In August 2026

Amarin Corporation plc is an Irish-incorporated pharmaceutical company with United States operations in Bridgewater, New Jersey, listed on Nasdaq under the ticker $AMRN. It owns one commercial product, icosapent ethyl, sold as VASCEPA in the United States and much of the world and as VAZKEPA in Europe, and it has no clinical pipeline behind it. Everything the company is worth today rests on how much of that single molecule can still be sold, at what price, and through whose sales force.

The shape of the business changed in June 2025, when Amarin signed an exclusive long-term licence and supply agreement with Recordati S.p.A. covering 59 countries focused on Europe. That agreement, together with a global restructuring programme targeting $70 million of annual operating expense savings, converted Amarin from a company that ran its own commercial infrastructure across Europe into one that sells through partners everywhere except the United States. On July 29, 2026 the company described the twelve months since as the first anniversary of a “fully partnered international commercial strategy”.

The second quarter of 2026, reported that day, gives the clearest picture of what the new shape produces. Total net revenue was $42.2 million, down 42 per cent from $72.7 million a year earlier. Operating expenses were $27.0 million, down 59 per cent. The net loss was $7.7 million, against $14.1 million. Cash and short-term investments stood at $314.6 million at June 30, 2026, up from $302.6 million at December 31, 2025, and the company stated it remained debt free. Chief Financial Officer Peter Fishman said Amarin had generated positive cash flow for the third consecutive quarter.

Two facts frame everything that follows. The first is that the revenue decline is largely mechanical: the year-ago quarter contained a $25.0 million upfront payment from Recordati that will not repeat, and European product revenue now arrives as transfer prices and royalties from a partner rather than as end-market sales booked by Amarin. The second is that on June 4, 2026 the Supreme Court of the United States decided Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. against Amarin, closing the legal route that had, for two years, been the main source of speculative upside attached to the shares.

What is left is a company with more cash than its own stock-market value, no debt, a declining but real United States franchise, a partner network covering close to 100 markets, a cost base roughly half what it was, and an investment bank retained to explore what to do next.

02 Icosapent Ethyl And The REDUCE-IT Evidence Base

Icosapent ethyl is a purified form of eicosapentaenoic acid, one of the two long-chain omega-3 fatty acids found in fish oil. It is not fish oil: the formulation is a single ethyl ester, manufactured to pharmaceutical standards and prescribed at four grams a day, and it contains no docosahexaenoic acid, the other omega-3 that in earlier cardiovascular trials was associated with a rise in low-density lipoprotein cholesterol.

VASCEPA was first approved by the United States Food and Drug Administration in July 2012 as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, defined as triglycerides at or above 500 mg/dL. That indication, known inside the company as the MARINE indication after the trial that supported it, is a small market and it never sold well on its own.

The second indication is the one that matters commercially and legally. REDUCE-IT was a cardiovascular outcomes study conducted over seven years and completed in 2018, following 8,179 patients at more than 400 sites in eleven countries, all of them already on statin therapy with low-density lipoprotein cholesterol controlled between 41 and 100 mg/dL and triglycerides between 135 and 499 mg/dL. The primary results were published in the New England Journal of Medicine in November 2018 and the total-events analysis in the Journal of the American College of Cardiology in March 2019. On the strength of that evidence the FDA approved VASCEPA in December 2019 for reduction of cardiovascular risk in statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes with additional risk factors.

REDUCE-IT Legacy, presented at ESC on August 28, 2026

A new post-hoc analysis of the same trial was presented at the European Society of Cardiology Congress in Munich on the morning of August 28, 2026 and highlighted by the company the same day. It asked two questions that the original analysis did not: whether the size of the benefit depends on how long patients actually stay on the drug, and whether the benefit persists after they stop.

On adherence. The intention-to-treat analysis of all 8,179 participants produced a 25 per cent relative risk reduction in the primary composite endpoint, which is non-fatal myocardial infarction, non-fatal stroke, cardiovascular death, coronary revascularisation or unstable angina. Among the 6,921 participants who stayed on study drug for at least a year and a half, the reduction was about 29 to 30 per cent. Baseline characteristics of that group were comparable to the whole cohort, and the pattern held in the secondary prevention population.

On persistence after stopping. In the secondary prevention cohort, 1,318 participants who had taken study drug for at least three months and then discontinued it, after a mean of 2.3 years on therapy, kept their Kaplan-Meier curves separated for the rest of the follow-up, with a hazard ratio of 0.73. The same hazard ratio of 0.73 applied to cardiovascular events occurring after discontinuation, with no apparent loss of benefit over the following one to four years; those participants were off the drug for a mean of 2.1 years. Chris Packard of the University of Glasgow, who presented the work, compared the pattern to the twenty-year follow-up of the West of Scotland Coronary Prevention Study, where five years of statin therapy was associated with benefits that persisted for two decades.

What it is and what it is not. This is an exploratory post-hoc analysis of patients who chose to stop the drug inside a double-blind trial, not a randomised comparison of stopping against continuing. People who stay on a medicine for years differ from people who do not, in ways a post-hoc analysis cannot fully adjust for, and the company itself calls the findings exploratory. It adds to the scientific record behind a product whose United States exclusivity has already gone, and it changes neither the label nor the revenue line. Its practical value is in the argument for adherence, which is a commercial argument in the markets where partners still sell the drug under patent.

The current United States label carries both indications. The cardiovascular one is written as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation, in adults with triglycerides at or above 150 mg/dL. The safety section is short and specific: an increased rate of atrial fibrillation or atrial flutter requiring hospitalisation, 3 per cent against 2 per cent on placebo, and an increased rate of bleeding, 12 per cent against 10 per cent, with the excess concentrated in patients on concomitant antithrombotic medication.

In Europe, marketing authorisation for VAZKEPA was granted by the European Medicines Agency in March 2021 and by the United Kingdom regulator in April 2021, both for reduction of cardiovascular risk in high-risk patients. The company states that VASCEPA has been prescribed more than thirty million times since launch, as the company puts it in its August 28, 2026 release.

The evidence base is still being worked. On August 24, 2026 Amarin listed five company-supported abstracts accepted for the European Society of Cardiology Congress in Munich, covering treatment adherence and legacy effects, sex differences in study discontinuation, coagulation biomarkers, lipoprotein(a) variability and the oxidation of lipoprotein(a) by eicosapentaenoic acid. These are post-hoc and mechanistic analyses of a trial that finished eight years ago, presented by academic collaborators. They shape how cardiologists read the drug; they do not create a new indication or a new revenue line.

03 The Generic Shock And What Survived It

The patent that protected the cardiovascular indication was tested in the District of Nevada and lost. On March 30, 2020, following a trial concluded in January of that year, the court ruled in favour of Dr. Reddy’s Laboratories and Hikma Pharmaceuticals USA, declaring several of Amarin’s patents covering the MARINE indication invalid. Amarin appealed as far as the Supreme Court and was unsuccessful.

Generic entry followed quickly. According to the company’s own filing, Hikma obtained FDA approval for the MARINE indication in May 2020 and launched the one-gram size in November 2020 and the half-gram in March 2023. Dr. Reddy’s was approved in August 2020 and launched in June 2021 and June 2023. Teva Pharmaceuticals USA was approved in September 2020 and launched in January 2023 and September 2022. All three remain active in the market.

The commercial effect was severe and is a matter of public record. Vascepa product revenue peaked at $607.0 million in 2020 and was $580.3 million in 2021. Total revenue for 2022 was $92.0 million. That is not a decline, it is a collapse, and it happened because the generics were priced far below the brand and because pharmacy benefit managers moved volume to them at speed. Amarin responded with a restructuring in 2022 that cut roughly 40 per cent of its workforce.

What survived is the franchise being valued today, and it survived in a specific shape. In the second quarter of 2026 Amarin’s share of the United States icosapent ethyl market was 48 per cent, up from 43 per cent in the second quarter of 2025, and branded VASCEPA prescriptions rose 14 per cent year on year. United States product revenue in the quarter was $32.2 million, down 12 per cent from $36.5 million. Volume is rising and revenue is falling, which is the arithmetic of a market where net price per prescription keeps going down.

For the full year 2026 the company expects United States volumes to remain consistent. It does not guide to a return to growth in United States revenue, and the second-quarter release attributes the decline explicitly to “continued generic competition in the IPE market and the resulting pressure on net pricing”.

The patent estate did not end with the case that was lost. The 2025 annual report states that Amarin has pending patent applications worldwide relating to potential new uses of icosapent ethyl or other derivatives of EPA, and to potential new formulations of them, and that patents maturing from those applications would expire between 2030 and 2043. The company attaches no programme, no timetable and no cost to them: its own risk factors state that it cannot reasonably estimate the timing, completion dates or costs of developing any derivative, combination or next-generation product candidate. A pending application is not a product, and none of this appears in any guidance the company has given. It is, however, the one route by which the intellectual property position around icosapent ethyl could change without a court.

04 June 4, 2026: The Supreme Court Closes The Skinny-Label Route

The generics were approved for the MARINE indication only. They carved the cardiovascular indication out of their labels, a practice permitted under United States law and known as a skinny label, because that indication was still under patent. In commercial reality, the great majority of icosapent ethyl prescriptions are written for cardiovascular risk reduction, so a generic sold on the narrow label captures demand generated by the patented use.

Amarin sued Hikma for induced infringement, arguing that the combination of the skinny label and Hikma’s public conduct amounted to actively encouraging doctors to prescribe the generic for the patented indication. The evidence cited included descriptions of the product as a generic equivalent of VASCEPA and press releases that quoted market sales figures largely attributable to the cardiovascular use.

The case ran for six years. The District Court dismissed the claim. On June 25, 2024 the Court of Appeals for the Federal Circuit reversed, finding that Amarin’s allegations plausibly stated a claim of active inducement. Hikma’s petition for rehearing en banc was denied on October 17, 2024. Hikma petitioned the Supreme Court on February 14, 2025, certiorari was granted on January 16, 2026, and the District Court proceedings were stayed. Oral argument was heard on April 29, 2026.

On June 4, 2026 the Supreme Court reversed the Federal Circuit and remanded the case, finding, in the words of Amarin’s own quarterly report, that “the Company failed to state a claim for active inducement, and thus, cannot withstand Hikma’s motion to dismiss”. The decision was unanimous and was written by Justice Jackson. The Court held that routine generic marketing conduct, including a skinny label, standard therapeutic-equivalence language and investor-facing press releases, does not by itself constitute active inducement under 35 U.S.C. section 271(b), and that inducement requires affirmative steps rather than regulatory compliance, omissions or vague statements.

Two consequences follow. The narrow one is that the specific damages claim against Hikma is gone at the pleading stage, and the case returns to the District Court in a posture where Amarin has lost. The wider one is that the skinny-label route is now materially safer for the generic industry as a whole, which removes any expectation that United States net pricing on icosapent ethyl improves through the courts.

The litigation still costs money. Amarin recorded litigation-related charges of $6.3 million in the second quarter of 2026 and $9.4 million in the first half, booked within general and administrative expense. Those charges are the single largest reason the company’s non-GAAP result and its reported result diverge as much as they do.

05 The United States Business: Share Up, Revenue Down

The United States is the only market where Amarin still sells directly, with its own commercial organisation, and it produced $32.2 million of the $42.2 million of second-quarter revenue. The dynamics there are unusual, and they separate cleanly into three numbers.

Market share is rising. Amarin held 48 per cent of the United States icosapent ethyl market in the second quarter of 2026 against 43 per cent a year earlier. Branded prescriptions rose 14 per cent year on year. That is a brand taking share back from generic competitors five years after those competitors arrived, which is not the normal pattern in a genericised molecule.

Revenue is falling anyway. United States product revenue was down 12 per cent in the quarter and 6 per cent in the first half, to $67.9 million from $72.2 million. The gap between rising volume and falling revenue is net price, and net price in this category is set by rebates negotiated with pharmacy benefit managers against a generic reference that costs a fraction of the brand.

The company’s guidance for the rest of 2026 is that United States volumes remain consistent. Read together with the pricing trend, that points to a United States line that continues to erode slowly rather than one that stabilises, unless mix or contracting changes.

The structural question this raises is what the United States commercial organisation is for. It is the largest remaining cost in the business, it defends a franchise whose revenue declines every quarter, and it is the one part of the operation that was not handed to a partner in 2025. Every scenario for the company runs through what happens to it.

06 The Recordati Agreement And The Fully Partnered Model

In June 2025 Amarin granted Recordati S.p.A. an exclusive licence, with the right to sublicense, to develop and commercialise VASCEPA in 59 countries focused on Europe, on the basis of the REDUCE-IT evidence. Amarin supplies finished product to Recordati at a price set in the agreement. Amarin received an upfront payment of $25.0 million, fully recognised in 2025, and is eligible for sales-based milestone payments totalling up to $150.0 million, each payable once, plus royalties on net sales in the territory.

The commercial base handed over was already built. VAZKEPA had reached national reimbursement and launch in Sweden in March 2022, Finland in December 2022, England, Wales and Northern Ireland in October 2022, Spain and the Netherlands in September 2023, Scotland in September 2023, Greece in June 2024, Portugal in September 2024, Italy in January 2025, Slovenia in October 2025, Romania in May 2026 and Austria in January 2026, with Denmark available under individual reimbursement since June 2022. Switzerland has been available under individual reimbursement since January 2023 on a Swissmedic approval. In Greece, Romania and Slovenia the local distribution agreements, with Vianex, Magnapharm and Salus respectively, were transitioned to Recordati.

At June 30, 2026 VAZKEPA was commercialised in eleven European countries, and VASCEPA or VAZKEPA was commercially available in 22 countries worldwide. In-market demand for VAZKEPA in Europe rose 69 per cent in the second quarter of 2026 against the second quarter of 2025.

The reported European numbers look worse than the underlying activity, and the reason is accounting rather than demand. European product revenue was $5.4 million in the quarter, down 17 per cent, because Amarin no longer books end-market sales in those countries: it books the transfer price of product shipped to Recordati, plus royalties. The company states that quarter-to-quarter European comparisons on a consistent partnered basis begin only in the third quarter of 2026, which means the first genuinely readable European comparison arrives with the results for the period ending September 30, 2026.

The strategic logic is straightforward. Recordati is an established cardiovascular specialist across Europe with an existing field force, and it carries the cost of pricing and reimbursement negotiations country by country. Amarin keeps a royalty and a supply margin without funding a European infrastructure. What Amarin gives up is control over the pace of the launch and most of the economics if the product does succeed.

07 China, Canada, MENA And The Rest Of The Partner Network

Outside the United States and the Recordati territory, Amarin sells through a syndicate of regional partners. The quarterly report lists them by dossier. Under the United States new drug application dossier sit HLS Therapeutics in Canada, Biologix FZCo across the Middle East and North Africa, and Eddingpharm for the China Territory, which covers mainland China, Hong Kong, Macau and Taiwan. Under the European Medicines Agency dossier sit Recordati for Europe, CSL Seqirus for Australia and New Zealand, Lotus Pharmaceuticals for Southeast Asia and Neopharm for Israel. The company describes the network as covering close to 100 markets.

China is the largest of the non-European out-licences and the oldest. The development, commercialisation and supply agreement with Eddingpharm was signed in February 2015. The transaction price disclosed in the quarterly report totals $40.081 million: a $15.0 million upfront fee in February 2015, $1.0 million on submission of the clinical trial application for the MARINE indication in March 2016, $5.0 million on its approval in March 2017, $3.0 million on submission of the application for the REDUCE-IT indication in October 2023, $15.0 million on its approval in June 2024, and $1.081 million of regulatory development support. Beyond that, Amarin is entitled to tiered double-digit royalties on net sales in the China Territory, escalating to the high teens, and to sales-based milestones ranging from $5.0 million to $50.0 million each, for a total of up to $120.0 million.

Volume in China is growing from a small base. Amarin reported 90 per cent year-to-date growth in in-market volume in China in the second quarter release. Across the whole partner network, in-market demand for VASCEPA and VAZKEPA rose 59 per cent in the second quarter of 2026 against the same quarter of 2025.

Two more launches are described as approaching. The company states that Singapore and South Korea are progressing toward anticipated near-term commercialisation, without naming a date. These are company-stated expectations rather than confirmed regulatory or launch dates.

The reported rest-of-world line does not yet reflect any of this smoothly. Rest-of-world product revenue was $1.4 million in the second quarter of 2026 against $3.5 million a year earlier, a 61 per cent fall, which Amarin attributes to normal variability in partner purchasing patterns and shipment timing across multiple geographies. For the first half the same line was $4.2 million against $3.5 million, up 19 per cent. A revenue line that swings from plus 19 per cent to minus 61 per cent depending on the window chosen is a line driven by when containers ship, not by how many patients take the drug.

08 Second Quarter 2026 In Numbers

Amarin reported the three months ended June 30, 2026 on July 29, 2026. The figures below are taken from that release and from the quarterly report on Form 10-Q filed the same day.

The revenue split by geography, for the same quarter: United States $32.2 million, down 12 per cent; Europe $5.4 million, down 17 per cent; rest of world $1.4 million, down 61 per cent; licensing and royalties $3.1 million, down 88 per cent. For the first half of 2026, total net revenue was $87.3 million against $114.8 million, a fall of 24 per cent, and the net loss was $18.2 million against $29.8 million.

Three movements inside that table explain the rest. The 88 per cent fall in licensing and royalty revenue is the $25.0 million Recordati upfront dropping out of the comparison; the underlying royalty stream from Recordati is inside the $3.1 million and is small. The 22 per cent rise in cost of goods sold against a 16 per cent fall in product revenue compressed gross margin from $50.4 million to $15.0 million, a gross margin rate falling from 69 per cent to 36 per cent of total revenue. And the operating loss narrowed anyway, to $12.0 million from $16.0 million, because $39.3 million of operating expense came out.

Amarin also publishes a non-GAAP result that strips stock-based compensation, restructuring, litigation-related charges and one-off transaction fees. On that basis the second quarter of 2026 was a profit of $0.8 million against a profit of $18.0 million a year earlier, and the first half was a loss of $1.0 million against a profit of $10.3 million. The non-GAAP figures are the company’s own presentation and exclude $6.3 million of litigation charges in the quarter.

09 The Cost Base After The $70 Million Programme

The cost programme announced alongside the Recordati agreement targeted approximately $70 million of annual operating expense savings. On July 29, 2026 the company stated the programme was complete.

The headline is that operating expenses fell $39.3 million, or 59 per cent, to $27.0 million. That comparison flatters, because the year-ago quarter carried $22.8 million of restructuring charges that were themselves the cost of the cuts. Excluding restructuring from both periods, operating expenses fell $16.6 million, or 38 per cent, and that is the number Chief Executive Aaron Berg used on the call day. Both figures appear in the company’s own release and both are correct; they answer different questions.

Where the money came out is unambiguous. Selling, general and administrative expense fell to $22.2 million from $38.7 million in the quarter, and to $43.3 million from $75.2 million in the first half. Research and development was broadly flat at $4.8 million in the quarter and $9.4 million in the half, which is what a company with no clinical pipeline spends: within that half-year figure, $0.45 million went to maintaining REDUCE-IT data and supporting presentations, $1.0 million to regulatory filing fees, $0.09 million to non-clinical research and $6.8 million to internal staffing and overhead, for $8.4 million excluding non-cash items, with a further $1.1 million of stock-based compensation on top.

Cost of goods sold is the line moving the wrong way, up 22 per cent in the quarter to $27.2 million and up 39 per cent in the half to $54.6 million, on higher product volumes recognised in the period. In a partnered model where product ships to licensees at a contractual transfer price, cost of goods sold and revenue no longer move together the way they did under direct sales, and gross margin percentage becomes a less stable number quarter to quarter.

Non-cash stock-based compensation fell to $2.1 million in the quarter from $4.3 million, and to $4.4 million in the half from $10.4 million. That halving is consistent with a much smaller headcount, and it also reduces the annual share issuance that equity compensation would otherwise create.

10 A Balance Sheet Larger Than The Market Value

At June 30, 2026 Amarin held $143.6 million of cash and cash equivalents, $0.2 million of restricted cash and $171.1 million of short-term investments. The company reports the operating total as $314.6 million, against $302.6 million at December 31, 2025 and $298.7 million a year earlier. It states it remained debt free.

The rest of the balance sheet: accounts receivable net of $92.9 million, down from $126.8 million at the year end; inventory of $164.1 million, down from $195.9 million; total current assets of $602.8 million; total assets of $624.4 million. On the other side, accounts payable of $18.8 million, accrued expenses and other current liabilities of $145.4 million, total current liabilities of $164.2 million, and total liabilities of $180.7 million, of which $5.3 million is a long-term operating lease liability. Total stockholders’ equity was $443.6 million. Accumulated deficit was $1.7255 billion, which is the accounting record of everything spent to get here.

Two ratios follow from those figures and both are unusual for a company of this size. Cash and short-term investments of $314.6 million exceed the entire stock-market value of the company, which was $297.2 million at the Finviz Elite reading of August 28, 2026. And book value per share of $443.6 million against 21.00 million American Depositary Shares outstanding puts the shares at roughly two thirds of stated equity, a price-to-book ratio of 0.66 according to Finviz Elite on August 24, 2026.

Neither ratio means the cash is free. Total liabilities of $180.7 million sit against those assets, the business still runs an operating loss, and a large part of stated equity is inventory and receivables rather than money in an account. Cash net of all liabilities was $133.9 million at June 30, 2026. What the figures do establish is that the company is not under financing pressure: there is no debt to refinance, no covenant to breach, and no maturity wall.

Cash generation, not just the cash balance, is the change the company points to. Amarin has now reported positive cash flow in three consecutive quarters, and it expects cash at December 31, 2026 to be approximately 10 per cent higher than at December 31, 2025. Applied to the $302.6 million year-end 2025 figure, that guidance implies roughly $333 million at the end of 2026.

One asset does not appear on the balance sheet at all. At December 31, 2025 Amarin held combined United States and non-United States net operating loss carryforwards of $1.0 billion, which do not expire, a total that fell by about $8.9 million from the prior year after reconciliation to the filed 2024 foreign returns. Alongside them sit $8.7 million of United States federal tax credit carryforwards and $3.3 million of state credits, which do expire, between 2026 and 2044. Those losses carry no value in the accounts because a full valuation allowance sits against them: the company does not currently expect to generate the taxable income needed to use them. For a purchaser that could use them the calculation is a different one, which is why a loss pool of that size is part of what any buyer would be pricing. Amarin’s own filing sets out the condition attached: using the Irish carryforwards depends on the operations of its Ireland-based subsidiary remaining genuinely active in Ireland, and on the tax treaties between Ireland and other countries not changing in a way that limits the offset.

11 The Inventory Question

Inventory of $164.1 million against quarterly product revenue of $39.1 million is the single strangest number on the balance sheet. It represents roughly four times a quarter’s product sales in finished goods and materials, carried at cost.

The direction of travel is the reassuring part. Inventory fell $19.5 million between March 31 and June 30, 2026, and $31.8 million between December 31, 2025 and June 30, 2026. The Chief Financial Officer described the approach as “a disciplined, data-driven approach to inventory management that optimizes working capital while protecting product access”. Working inventory down converts a balance-sheet asset into cash without selling more product, and it is part of why cash rose while the company was still loss-making.

The risk attached to it is equally plain. Icosapent ethyl capsules have a finite shelf life, and inventory built for a larger commercial footprint than the company now operates carries the possibility of write-downs if it cannot be sold or shipped to partners before it expires. No such charge has been taken in the periods reported here.

Quarter by quarter, the inventory line moves together with cash and has to be read alongside it. If cash keeps rising while inventory keeps falling, a meaningful part of the cash improvement is the unwinding of working capital, which is finite by definition. Amarin’s own guidance of roughly 10 per cent cash growth for 2026 does not break out how much comes from operations and how much from working capital.

12 What The Company Has Guided To For 2026

The company set out its expectations for the full year 2026 in the second-quarter release. Stated plainly, they are: continued growth in international markets; maintenance of VASCEPA’s United States market share; an improved operating expense profile; and positive cash flow generation. On the specifics, United States volumes are expected to remain consistent through the year, and cash at December 31, 2026 is expected to be approximately 10 per cent higher than at December 31, 2025.

What that guidance does not contain is as informative as what it does. There is no revenue guidance, in dollars or in growth rates. There is no earnings guidance, GAAP or non-GAAP. There is no date by which the company expects to reach sustained profitability, and no milestone schedule for the Recordati or Eddingpharm sales-based payments. The $150.0 million of Recordati milestones and the $120.0 million of Eddingpharm milestones are contractual maximums tied to annual net sales thresholds that have not been disclosed, and neither the thresholds nor the timing are public.

The guidance is therefore best read as a commitment to the shape of the business rather than to its size: costs stay down, cash goes up, share holds, international volume grows. Each of those four can be checked against the third-quarter release without needing a forecast.

13 Barclays, The Strategic Process And The Board

The line in the second-quarter release that has the widest range of outcomes attached to it is a single clause in the Chief Executive’s quote. Aaron Berg said the company continues to “work closely with Barclays, our exclusive financial advisor, to explore additional potential pathways to further enhance shareholder value”.

A company with no debt, cash exceeding its market capitalisation, a completed cost programme, a single asset sold through partners and an exclusive financial adviser retained is describing a strategic review in the language public companies use for one. The phrase “additional potential pathways” is not defined in the release, and Amarin has announced no transaction, no timetable, no process stages and no counterparties.

The pathways that a company in this position can pursue are known in general terms: a sale of the whole company; a sale or further out-licensing of the United States commercial rights, which are the only rights not already partnered; a return of capital to shareholders; a reverse merger or an acquisition that puts the cash to work in a different asset; or continuing as an independent royalty-and-supply business. Nothing in the public record indicates which of these, if any, is under consideration.

The board composition is relevant context here. Amarin’s directors, as put to the annual general meeting held in Dublin on May 13, 2026, are Aaron Berg, Patrice Bonfiglio, Keith L. Horn, Odysseas Kostas, Louis Sterling III, Diane E. Sullivan and Michael Torok. Several have direct professional links to Sarissa Capital Management, an activist investor focused on healthcare. The 2026 proxy statement describes Patrice Bonfiglio as an adviser to Sarissa Capital and a former president of the firm, and Odysseas Kostas, who chairs the board, as an adviser to Sarissa where he was previously a partner, senior managing director and head of research. Boards constituted this way generally exist to pursue a transaction or a return of capital rather than a long build.

That involvement is considerably older than the current board, and the filings date it precisely. Sarissa’s quarterly position reports show no Amarin holding at March 31 or June 30, 2021, then 8,500,000 ordinary shares at September 30, 2021 and 19,250,000 at December 31, 2021. On January 24, 2022 Sarissa Capital Management and Alexander J. Denner filed a Schedule 13D reporting 24,000,000 ordinary shares, 6.06 per cent of the 395,825,887 then outstanding, bought for an aggregate price of approximately $106.9 million. That is about $4.45 an ordinary share, which at the ratio in force today works out at roughly $89 per American Depositary Share. The event date on the filing is January 13, 2022, the day the holding crossed five per cent. The board changed a year later: Patrice Bonfiglio, Keith L. Horn, Odysseas Kostas and Paul Cohen joined in February 2023, Oliver O’Connor in April 2023 and Michael Torok in April 2025.

At June 30, 2026 Sarissa reported 1,673,395 American Depositary Shares, which is 33.5 million ordinary shares, or roughly 7.9 per cent of the count on the cover of the latest quarterly report, and the position was unchanged across the three preceding quarters. What the filings do not give is a blended cost for the shares added after the initial block, so no single average entry price for the whole holding can be stated from the public record.

That changed on August 24 and 25, 2026, and it is the most concrete new fact on this file. Amendment No. 16 to the Schedule 13D, filed by Sarissa Capital Management LP and Alexander J. Denner at 6:56 p.m. Eastern on August 27 with an event date of August 25, reports a holding of 25,743,900 ordinary shares, approximately 6.09 per cent, measured against the 422,456,685 ordinary shares outstanding at July 24, 2026 as disclosed in the second-quarter Form 10-Q. Exhibit 17 to that filing, headed Schedule of Transactions in ADSs of the Issuer During the Past 60 Days, lists 686 separate sales across two sessions and no purchases: 33,842 ADSs on August 24 at an average of $14.0093 and 352,463 ADSs on August 25 at an average of $14.0019. That is 386,305 ADSs for $5,409,262, all of it within a few cents of $14.00.

Merlintrader reconstruction, which the filing does not state: 386,305 ADSs at twenty ordinary shares each is 7,726,100 ordinary shares, which set against the residual 25,743,900 implies a starting position of 33,470,000 ordinary shares. The 1,673,395 ADSs reported at June 30 are 33,467,900 ordinary shares, so the reconstruction lands within 2,100 shares of the last disclosed holding, and the fall from 7.92 per cent to 6.09 follows from it. The document reports the residual holding and the transactions; the percentage it started from is arithmetic, not disclosure.

What the selling means is a matter of judgement rather than record. An activist whose associates sit on the board, selling at fourteen dollars while a strategic review is open and unconcluded, is a fact worth having in front of you; the filing gives no reason for the sales and none should be invented for it. Sarissa remains above the five per cent threshold and therefore still reports.

None of that is a prediction. The strategic review may produce nothing, may take longer than shareholders expect, or may conclude that the current model is the best available. What can be said with certainty is that it is disclosed, that it is ongoing as of July 29, 2026, and that any announcement arising from it would be the single largest event for the shares in either direction.

14 Management, And The ADS Ratio Change That Rewrites The Chart

Aaron Berg is President and Chief Executive Officer. He is also a director, re-elected at the May 13, 2026 annual general meeting. Peter Fishman is Chief Financial Officer. Both were quoted in the second-quarter release, Berg on the commercial and strategic side and Fishman on the cost base, cash flow and inventory.

The current management team is the one that executed the pivot: the Recordati agreement in June 2025, the global restructuring that followed, and the completion of the $70 million savings programme announced as done in July 2026. Their predecessor, former chief executive Karim Mikhail, filed a complaint against the company in the Superior Court of New Jersey on March 31, 2023 alleging constructive termination and seeking unspecified damages for breaches of his employment agreement, the executive severance and change of control plan, and the implied covenant of good faith. The case moved to the United States District Court for the District of New Jersey in April 2023 and is disclosed in the company’s filings.

One corporate action from 2025 changes how every per-share number here must be read. Effective April 11, 2025 Amarin adjusted the ratio of its American Depositary Shares to ordinary shares, from one ADS representing one ordinary share to one ADS representing 20 ordinary shares. Holders of fractional ADSs received cash. The change did not alter the number of ordinary shares outstanding and was not a reverse split of the underlying equity, but for anyone holding or quoting the Nasdaq-listed security the effect on the quoted price and on per-ADS figures is the same as a one-for-twenty consolidation.

The practical consequence is that historical $AMRN prices quoted before April 2025 are not comparable with prices quoted after it unless they have been restated.

The share count itself starts from the figure the company states on the cover of its own quarterly report: 422,456,685 ordinary shares outstanding at July 24, 2026. Weighted average ordinary shares used for the earnings calculation were 416.4 million basic in the second quarter of 2026 against 414.5 million a year earlier, an increase of less than half a per cent; the gap between the two figures is treasury stock held by the company, which carried a balance of $69.3 million at June 30, 2026. At twenty ordinary shares per ADS, 422.5 million ordinary shares correspond to roughly 21.1 million ADS. Finviz Elite reported 21.00 million ADS outstanding on August 24, 2026. The gap is not rounding: the cover of the second-quarter Form 10-Q reports 20,632,560 ADSs outstanding against 422,456,685 ordinary shares, so roughly 9.8 million ordinary shares are held outside the ADS programme. The 21.12 million figure is the ADS equivalent of the whole share count, not a count of ADSs in issue, and the market capitalisation on this page is calculated on it.

15 Market Snapshot And Analyst Coverage

The price and market capitalisation were reread from Finviz Elite on August 28, 2026. The other market data below was read on August 24, 2026 and refers to the close of August 21, 2026. Market readings change continuously and are the fastest-ageing figures among those reported.

Three of those readings sit oddly together. Average daily volume of about 73,900 ADS makes this a thin security in dollar terms, around $1 million of turnover a day, which means position sizes that are trivial for an institution are not trivial for the order book. Short interest at 2.54 per cent of float is low, so the price is not being set by a crowded short position. And a beta of 0.76 on a stock whose story is idiosyncratic says the shares have been moving on their own news rather than with the market.

Analyst coverage is thin and hard to document to the standard used for the rest of the data reported. The consensus price target carried by Finviz Elite on August 24, 2026 was $12.50, which sits below the price of $14.07 read on August 28, 2026. Individual notes, the houses that issued them and their dates could not be confirmed against the issuing firms, so no table of ratings is presented here. A consensus built on a handful of notes on a company with a market capitalisation under $300 million is a weak signal in either direction, and a target below the market price is not in itself a prediction of decline.

16 Retail Sentiment On Stocktwits

Stocktwits publishes a public sentiment stream for each ticker. The readings below were taken on August 24, 2026 and describe self-reported tags posted by retail traders and non-professional investors. They are not analyst research, they carry no accountability, and they are included because a thinly traded small capitalisation is more exposed to retail flow than a large one.

The month behind the reading is more informative than the reading itself. The normalised community sentiment score ran at 50 on July 21, climbed through the second-quarter release on July 29 to 68, then to 76 on July 31 and to a peak of 91 on August 3. It then fell for two full weeks, through 43 on August 11 and 36 on August 13, to 19 on August 17, 15 on August 18 and a low of 12 on August 19, before recovering to 45 on August 21. No company announcement was made between August 3 and August 21.

The two numbers in the box appear to contradict each other and do not. The share of sentiment-tagged messages marked bullish was 93.75 per cent on August 24, while the normalised community score was 46, which the platform labels neutral. The first counts the small number of posts on which somebody clicked a tag; the second is a broader model of the stream. A high tagged-bullish percentage on a low absolute count measures the absence of posted disagreement, not agreement.

Message volume on August 24 was labelled normal, at a score of 48, and the ticker ranked 47th on the platform’s trending list. Watchers of the $AMRN stream numbered 30,399. That watcher count, on a stock with about $1 million of daily turnover, is a legacy of the 2018 to 2021 period when this was one of the most heavily followed retail names in biotechnology.

17 The Catalyst Map

Amarin has no PDUFA date, no advisory committee meeting and no pivotal readout pending. There is no clinical pipeline behind icosapent ethyl. The catalyst map is therefore commercial, financial and corporate, and it looks nothing like that of a development-stage biotechnology company.

The two dated items are the ESC Congress, now concluded, and the third-quarter results in the autumn. The ESC presentations are academic analyses of a completed trial and change no forecast on their own. The third-quarter results carry more weight than a routine quarter, because Amarin has stated that consistent European comparisons under the partnered model begin with that period, and because it is the first checkpoint against all four elements of the 2026 guidance.

Everything else on the list has no date, and the largest of them, the strategic process, has no disclosed timetable at all.

18 Risks And Red Flags

The revenue base is still declining. Total net revenue fell 42 per cent in the second quarter and 24 per cent in the first half. Part of that is the Recordati upfront dropping out of the comparison, but United States product revenue, the largest line and the one not affected by the accounting change, fell 12 per cent in the quarter and 6 per cent in the half on rising volumes. Net price per prescription is doing the damage.

The legal route is closed. The Supreme Court decision of June 4, 2026 removed the induced infringement claim against Hikma at the pleading stage and made the skinny-label route safer for generic manufacturers generally. Any thesis that assumed United States pricing would improve through litigation no longer has a mechanism.

One product, no pipeline. Research and development spending of $9.4 million in the first half is maintenance of an existing dossier, not the development of anything new. There is no second asset to absorb a further deterioration in icosapent ethyl.

Inventory of $164.1 million. Four quarters of product sales sit on the balance sheet at cost. Working it down releases cash, which is happening, but it also concentrates the risk of a write-down if product cannot be shipped or sold before it expires.

Gross margin compression. Cost of goods sold rose 22 per cent in the quarter while product revenue fell 16 per cent, taking gross margin from $50.4 million to $15.0 million. In a partner-supply model the margin depends on contractual transfer prices, and Amarin has not disclosed them.

The partnered model transfers economics as well as cost. European in-market demand grew 69 per cent while European revenue booked by Amarin fell 17 per cent. Success in Europe now shows up as royalties and supply margin, which is a fraction of end-market value, and Amarin no longer controls the pace.

Liquidity. Average daily volume of roughly 73,900 ADS, about $1 million a day at the last close, makes both entry and exit slower than the market capitalisation would suggest.

Strategic uncertainty. A disclosed process with an exclusive financial adviser and no timetable is an open-ended situation. It can end in a transaction, a return of capital, or nothing at all, and shareholders have no information on which of those is more likely.

Concentration in one commercial organisation. The United States field force is the largest remaining cost and defends the only market not handed to a partner. Any decision about it, in either direction, changes the shape of the business materially.

19 Merlintrader Health Score

The Merlintrader Health Score is a one-to-five reading of how robust a company looks over the next twelve to eighteen months, built on five weighted pillars. It is a description of financial and operational fragility, not a view on the share price, and it is not a recommendation to buy, sell or hold anything.

Weighted, that gives a Merlintrader Health Score of 3.6 out of 5 as of August 24, 2026. The profile is unusual: the balance-sheet pillars score at the top of the scale and the catalyst pillar near the bottom. A company can be extremely hard to break and still have very little scheduled to happen to it, and that combination is what the score is describing here.

20 Scenarios

The scenarios below are descriptions of how the situation could develop given what is on the public record. They carry no probabilities, no price levels and no recommendation, and they are not forecasts.

The two cases are not symmetric in what would settle them. The constructive case depends on events that are not scheduled: a transaction, a capital return, a milestone. The negative case depends on a trend that is already measurable every quarter. The third-quarter results, expected in late October 2026 though not yet confirmed, are the first point at which the partnered European model can be read on a consistent basis.

21 Bottom Line

Amarin in August 2026 is a company that has finished restructuring itself and has not yet decided what it is for. The clinical story ended in 2018 with REDUCE-IT, the pricing story ended in 2020 with generic entry, and the legal story ended on June 4, 2026 when the Supreme Court found unanimously that the induced infringement claim against Hikma could not survive a motion to dismiss.

What remains is measurable. One product, sold directly in the United States and through partners in close to 100 markets. Total net revenue of $42.2 million in the second quarter of 2026, down 42 per cent, with United States product revenue of $32.2 million falling 12 per cent on prescriptions rising 14 per cent. Operating expenses of $27.0 million, cut by 59 per cent, from a $70 million savings programme the company has declared complete. A net loss of $7.7 million. Cash and short-term investments of $314.6 million at June 30, 2026, no debt, equity of $443.6 million, three consecutive quarters of positive cash flow, and a share count that has barely moved.

Set against a market capitalisation of $297.2 million at the August 28, 2026 reading, those figures describe a company valued at less than the cash on its balance sheet, which usually happens when the market expects the cash to be consumed or the operating business to keep destroying value. Whether that expectation is correct depends on two things that are not yet public: what the partnered international model produces once the comparisons become consistent from the third quarter of 2026, and what comes out of the process being run with Barclays.

The next dated checkpoint already behind the company is the European Society of Cardiology Congress in Munich, held August 28 to 31, 2026, where five company-supported analyses were presented, and the third-quarter results expected in late October 2026, though that date has not been confirmed by the company.

Related Research On Merlintrader

• Biotech Stock Hubs — the full Merlintrader index of biotech and healthcare stock hubs, with the date each one was last verified.
• $AMRN turnaround check, January 2026 — earlier Merlintrader coverage, written before the Supreme Court decision of June 4, 2026 and before the second-quarter 2026 results.
• $AMRN company history and analysis — the ten-year record from REDUCE-IT to generic entry, with the revenue figures for each year.
• Free Biotech Catalyst Calendar — PDUFA dates, advisory committee meetings and clinical readouts across the sector.